The pharmaceutical company Roche
Achieved success in China. The local health authority (CNDA) has departed
the Alecensa medication for the treatment of ALK-positive, not
small cell lung cancer also, such as the Swiss company on
Monday announced.
The decision of the CNDA follows an accelerated pace
Admission procedure, the so-called "priority review". corresponding
Approvals have already been granted by the European Healthcare Authority EMA
and the FDA issued in the US./cf/AWP/tav
ISIN US7170811035 CH0012032048
AXC0038 2018-08-20 / 07: 40
Copyright dpa-AFX Business News GmbH. All rights reserved. Redistribution, republishing or permanent storage without the express prior permission of dpa-AFX is not permitted.
Source link